The Microbiome Business & Science Briefing
MicrobimeTimes
Reporting on The Latest Microbiome Business & Scientific Developments
TRENDING
MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination• Evvy Raises $40M Series B to Scale AI-Powered Precision Diagnostics & Care Platform for Women’s Health• Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02• GutAlive®: Microbiota Collection and Transport in Anaerobic Conditions• From Discovery to Disease Prevention: How the Biose–Siolta Partnership is Advancing a New Generation of Live Biotherapeutics• A pioneering gut bacterium passes Europe’s food-safety review under the EU Novel Food Regulation•

Microbiome Times

Global biotech executive to boost microbiome drug development for Asia Pacific
Finance

Global biotech executive to boost microbiome drug development for Asia Pacific

FEB 11, 2021
Probiotics to Provide Holistic Health Benefits
Biotics and Supplements

Probiotics to Provide Holistic Health Benefits

FEB 10, 2021
Fecal transplant turns cancer immunotherapy non-responders into responders
Editor's Choice

Fecal transplant turns cancer immunotherapy non-responders into responders

FEB 10, 2021
Investigating the removal of dry biofilm with probiotic cleansers
Biotics and Supplements

Investigating the removal of dry biofilm with probiotic cleansers

FEB 9, 2021
MIND and Mediterranean diets associated with later onset of Parkinson’s disease
Gut-Brain Axis

MIND and Mediterranean diets associated with later onset of Parkinson’s disease

FEB 5, 2021
Lactobacillus manipulates bile acids to create favorable gut environment
Biotics and Supplements

Lactobacillus manipulates bile acids to create favorable gut environment

FEB 4, 2021
Da Volterra Receives first Authorizations from Regulatory Authorities in EU Countries to Initiate Phase 3 Clinical Trial Evaluating Microbiome Protector DAV132
Clinical & Manufacturing

Da Volterra Receives first Authorizations from Regulatory Authorities in EU Countries to Initiate Phase 3 Clinical Trial Evaluating Microbiome Protector DAV132

FEB 3, 2021
Microbiome-based diagnostics and biomarkers: Changing the paradigm in microbiology and medicine
Reports

Microbiome-based diagnostics and biomarkers: Changing the paradigm in microbiology and medicine

FEB 3, 2021
Microbiome-based diagnostics and biomarkers: Changing the paradigm in microbiology and medicine
Premium Content

Microbiome-based diagnostics and biomarkers: Changing the paradigm in microbiology and medicine

FEB 2, 2021
Study suggests that gut fungi are not associated with Parkinson’s disease
Gut-Brain Axis

Study suggests that gut fungi are not associated with Parkinson’s disease

FEB 1, 2021
Why microbiota samples should be collected in all clinical trials?
Clinical & Manufacturing

Why microbiota samples should be collected in all clinical trials?

JAN 26, 2021